New PET tracer aims to spot Alzheimer's plaques safely

NCT ID NCT05731440

Ongoing Diagnosis Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new radioactive tracer called Fluselenamyl for PET scans to detect beta-amyloid plaques in the brain, a hallmark of Alzheimer's disease. Researchers will check its safety and how well it works in 60 healthy volunteers and people with mild cognitive impairment or Alzheimer's. The goal is to improve diagnosis by comparing this new tracer with an existing one.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-Fluselenamyl (a radioactive tracer for PET scans)
What this could lead to: If successful, this could provide a safer and more accessible way to detect Alzheimer's-related brain changes early, aiding diagnosis and research.
What could go wrong: This is an early-phase safety and imaging study with only 60 participants. The tracer may not prove more effective than existing methods, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.